TCR-mimetic-CAR therapy / JURA Bio - LARVOL DELTA

Discovery and characterization of a first-in-class de novo AI-designed TCR-mimetic-CAR targeting HLA-A2:01+ PRAME+ cancers (SITC 2025) - "Furthermore, PRM-CAR-T and PRM-CAR-NKT cells showed no activity against target-negative cancer cells, including a PRAME-knockout cell line, or a broad panel of normal human primary cells derived from various tissues, confirming the high specificity of the therapy.Conclusions In summary, these data provide strong in vitro evidence for the potency and specificity of PRM-CAR cells. This novel, TCRm-based CAR therapy, represents a promising new treatment modality for HLA-A2:01-positive patients with PRAME-positive malignancies."

IO biomarker • Melanoma • Oncology • Solid Tumor • HLA-A • IFNG • PRAME • TNFA